Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — H1 2022 Earnings Presentation
13 slides from Imricor Medical Systems's earnings presentation, Aug 31, 2022
Slide 1: H1 FY22 Investor Presentation
For personal use only H1 FY22 Investor Presentation August 2022 IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer For personal use only The material contained in this presentation is intended to be general background those which we expect, depending on the outcome of various factors. Investors and others information on Imricor Medical Systems, Inc. (Imricor) and its activities. are cautioned not to p
Slide 3: Introduction to Imricor
For personal use only Introduction to Imricor
Slide 4: Transitioning cardiac ablation into a new kind of lab
Transitioning cardiac ablation into a new kind of lab Conventional x-ray EP lab iCMR EP lab (interventional cardiac magnetic resonance) For personal use only X-ray to iCMR Everyone else Only Imricor Physicians, Patients, Hospitals Imricor Annual consumable device revenue per iCMR • Same kinds of too
Slide 5: Business Update and Outlook
For personal use only Business Update and Outlook
Slide 6: H1 Financial Highlights
H1 Financial Highlights For personal use only • Consumable product revenues of US$229 thousand in 1H22, up 159% compared to 1H21 and 12% compared to 2H21 • Net loss of US$9.8 million, down 2% compared to 1H21 and flat with 2H21 • Maintained cash balance of US$9.1 million at 30 June, 2022 INVESTOR PR
Slide 7: Profit and loss
Profit and loss US$’000 HY22 HY21 For personal use only Commentary Revenue 538 366 • Costs and non-R&D expenses increased slightly in 2022 primarily due to additional staffing ($170k) and increased travel Costs and non-R&D expenses (5,588) (5,249) spend ($94k). R&D expenses (4,319) (4,537) • R&D exp
Slide 8: Balance sheet
Balance sheet US$’000 Jun-22 Dec-21 Commentary For personal use only Cash and cash equivalents 9,107 18,516 • Generally, most balance sheet accounts are Accounts receivable 234 95 consistent with 31 December. Inventory 2,328 2,583 Other current assets 1,332 1,505 Total current assets 13,001 22,699 •
Slide 9: Cash flow
Cash flow For personal use only US$’000 HY22 HY21 Commentary Net loss (9,776) (9,962) • Other non-cash adjustments were flat vs. prior Other non-cash adjustments 1,369 1,328 comparative period as an increase in inventory reserves was mostly offset by a decrease in stock-related Change in other asset
Slide 10: Focus of H1
Focus of H1 For personal use only 1) Commencing procedures across contracted sites 2) Ramping up procedure volumes Sales 3) Advancing new sites through process 4) Progressing toward VT clinical trial VT INVESTOR PRESENTATION | 10
Slide 11: Accomplishments in H1
Accomplishments in H1 • Commenced procedures at 3 sites who were not performing procedures during pandemic For personal use only • Also installed and trained an additional 3 sites to commence procedures in Q3 • Increased consumable device revenue 159% over H1 2021 • Strong second quarter with contin
Slide 12: Our focus for H2
Our focus for H2 Focused on three key areas For personal use only 1 2 3 Commercialisation Growth Initiatives Products • Steady re-launch of site • Advance strategy around • Consumable devices for expansion in H2 clinical trials that expand VT ready for clinical • Activating sites indications in Euro
Slide 13: Contact Information
Contact Information For personal use only Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Rest of World Media: Nick Twohy Director of Marketing, Imrico
Imricor Medical Systems — H1 2022 Earnings Presentation on 6ix